Lineage-specific chimerism analysis in nucleated cells, T cells and natural killer cells after myeloablative allogeneic hematopoietic stem cell transplantation by Goh, Ri-Young et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
VOLUME 46ㆍ NUMBER 1ㆍ March 2011
THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE
Lineage-specific chimerism analysis in nucleated cells, T cells and 
natural killer cells after myeloablative allogeneic hematopoietic 
stem cell transplantation
Ri-Young Goh
1, Sung-Hyun Kim
2, Jin-Yeong Han
1
Departments of  
1Laboratory Medicine, 
2Internal Medicine, Dong-A University College of Medicine, Busan, Korea
p-ISSN 1738-7949 / e-ISSN 2092-9129
DOI: 10.5045/kjh.2011.46.1.18
Korean J Hematol 2011;46:18-23.
Received on February 24, 2010
Revised on February 8, 2011
Accepted on February 8, 2011
Background
Chimerism analysis is an important tool for assessing the origin of hematopoietic cells 
after allogeneic stem cell transplantation (allo-SCT) and can be used to detect impending 
graft rejection and the recurrence of underlying malignant or nonmalignant diseases. 
Methods
This study included 24 patients who underwent myeloablative allo-SCT. DNA was ex-
tracted from nucleated cells (NCs), T cells, and natural killer (NK) cells, and the chimerism 
status of these cell fractions was determined by STR-PCR performed using an automated 
fluorescent DNA analyzer. 
Results
Twenty-three out of the 24 patients achieved engraftment. Mixed chimerism (MC) in NCs, 
but not in T cells and NK cells, was significantly correlated with disease relapse. MC in 
all cell fractions was correlated with mortality. Ten patients (41.6%) developed extensive 
chronic GVHD. Six patients had MC in T cells, and 3 of them had chronic GVHD. Four 
patients with MC and relapse received donor lymphocyte infusion (DLI), and among them, 
3 had secondary relapse. Further, the chimerism status differed among different cell line-
ages in 6 patients with myeloid malignancies.
Conclusion
The implications of MC in lymphocyte subsets are an important area for future research. 
Chimerism analysis in lineage-specific cells permits detection of relapse and facilitates 
the monitoring of therapeutic interventions. These results can provide the basic data for 
chimerism analysis after myeloablative SCT.
Key Words Lineage-specific chimerism, Myeloablative stem cell transplantation, T 
cells, Natural killer cells
*This study was supported by a grant of the 
Korea Health 21 R&D Project, Ministry of 
Health & Welfare, Republic of Korea 
(A050099).
Correspondence to
Jin-Yeong Han, M.D., Ph.D.
Department of Laboratory Medicine, 
Dong-A University College of Medicine, 1, 
3-ga, Dongdaesin-dong, Seo-gu, Busan 
602-715, Korea
Tel: ＋82-51-240-5323
Fax: ＋82-51-255-9366
E-mail: jyhan@dau.ac.kr
Ⓒ2011 Korean Society of Hematology
INTRODUCTION
  Chimerism analysis is an important tool used to assess 
the origin of hematopoietic cells after allogeneic stem cell 
transplantation (allo-SCT). After allo-SCT, both donor and 
recipient hematopoietic cells can coexist in the recipient, 
and this state is called mixed chimerism (MC). In patients 
with MC, the percentage of recipient cells could remain 
stable, increase, or spontaneously decrease over time [1-8]. 
The presence of recipient cells in the peripheral blood (PB) 
or bone marrow (BM) of patients during the posttransplant 
period is an important prognostic indicator of transplant 
rejection, disease relapse, and graft-versus-host disease 
(GVHD) [9-12]. 
  Several methods have been developed to assess the level 
of donor engraftment after allo-SCT. Fluorescent in situ hy-
bridization of sex chromosomes (XY-FISH) and PCR-based 
analysis of polymorphic DNA sequences are the most widely 
used techniques, and real-time PCR techniques based on 
analysis of the Y chromosome or on single nucleotide poly-
morphisms (SNPs) are being evaluated. Currently, fluo-
rescence-based PCR amplification of short tandem repeats 
(STRs) is the gold standard for analyzing post-transplant 
chimerism and has been used in most studies [13-15].
  PB or BM is most often used for chimerism analysis, with Korean J Hematol 2011;46:18-23.
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Table 1. Patient characteristics and their clinical outcomes after transplantation.
UPN
Sex/Age 
(years)
Diagnosis
Donor–recipient 
relationship 
status
HLA 
match
ABO
match
Source of 
stem cells
CD34
＋ 
cells
(×10
6/kg)
Case of
DLI
Case of
relapse
Status at last 
follow-up
Outcome
1 M/23 ALL Related Yes Major BM 4.26 Yes Yes MC Expired
2 M/45 CML Related Yes Minor BM 2.30 No Yes CC Alive
3 M/34 AML Related Yes Major PBSC 6.00 No Yes MC Expired
4 F/33 AML Related Yes Major BM 7.45 No No CC Alive
5 M/31 AML Related Yes Match PBSC 7.38 Yes Yes MC Expired
6 M/31 CML Related Yes Minor PBSC 7.58 No No CC Alive
7 M/18 CML Unrelated Yes Major PBSC 2.06 Yes Yes Relapse Expired
8 F/33 AML Unrelated Yes Major BM 0.84 No No CC Alive
9 F/50 SAA Related Yes Match PBSC 4.37 No No CC Alive
10 M/33 MDS Unrelated Yes Minor BM 0.84 No Yes Relapse Expired
11 F/29 SAA Related Yes Minor PBSC 3.40 Yes Yes CC Alive
12 M/44 AML Related Yes Minor PBSC 4.71 No No CC Alive
13 F/36 AML Related Yes Minor PBSC 6.61 No No CC Alive
14 F/56 MDS Related Yes Minor PBSC 3.50 No No CC Expired
15 M/20 AML Unrelated One (Cw)
mismatch
Minor BM 3.02 No No CC Expired
16 M/19 ALL Related Yes Minor PBSC 7.20 No No CC Alive
17 M/45 SAA Related Yes Major PBSC 1.50 No Yes CC Alive
18 F/15 AML Unrelated Yes Minor BM 1.95 No No CC Alive
19 M/47 MDS Related Yes Major PBSC 5.32 No No CC Expired
20 F/41 MDS Related Yes Minor PBSC 0.16 No No CC Alive
21 F/43 AML Related Yes Major PBSC 4.00 No No CC Alive
22 M/49 AML Related Yes Match PBSC 7.85 No No CC Alive
23 F/37 PNH Related Yes Match PBSC 3.10 No No CC Alive
24 M/37 MDS Unrelated Yes Match BM 2.76 No No CC Alive
Abbreviations: UPN, unique patient number; CD34
＋, positive selection of CD34 cells; DLI, donor leukocyte infusion; M, male; BM, bone 
marrow; MC, mixed chimerism; CC, complete chimerism; PBSC, peripheral blood stem cell; F, female; SAA, severe aplastic anemia; MDS, 
myelodysplastic syndrome; PNH, paroxysmal nocturnal hemoglobinuria.
or without further manipulation of different cell subpo-
pulations. It is important to realize that patients could show 
complete chimerism (CC) in one cell type, for example, T 
cells, whereas others could be totally or in part recipi-
ent-derived. This is called split chimerism [3, 8].
  Many studies have investigated nonmyeloablative con-
ditioning regimens for split chimerism. We compared do-
nor-recipient chimerism levels in nucleated cells (NCs) and 
lineage-specific cell subtypes, namely, T cells and natural 
killer (NK) cells, after myeloablative allo-SCT by using multi-
plex STR-PCR in order to determine the sensitivity and 
specificity for the detection of minimal residual disease. 
Moreover, we analyzed the correlation between chimerism 
status and clinical outcome, including cumulative incidence 
of GVHD and relapse. There have been few studies in Korea 
about chimerism or discrepant results among various cell 
lineages. 
MATERIALS AND METHODS
1. Patients and specimens
  This study included 24 patients who underwent allo-SCT 
between December 2001 and September 2008 in our in-
stitution; patient characteristics are shown in Table 1. 
Ethylenediaminetetraacetic acid (EDTA)-treated PB samples 
were obtained from both the donor and recipient before 
transplantation. After allo-SCT, recipient PB samples were 
drawn every month for the first 3 months and then every 
3 months for 2 years or until the recipient’s death. NCs 
were isolated by density gradient centrifugation by using 
Ficoll-Paque (d=1.077 g/mL; Pharmacia, Sweden). T cells 
(CD3
＋) and NK cells (CD56
＋) cells were separated using 
the RosetteSep antibody cocktail (Stem Cell Technologies; 
Vancouver, BC, Canada) according to the manufacturer's 
instructions, with minor modifications. Genomic DNA was 
extracted from NCs and from CD3
＋ and CD56
＋ cells by 
using the QIAamp Blood Kit (Qiagen; Chatsworth, CA, USA). 
2. Chimerism analysis
  Chimerism studies were performed using the AmpF/STR 
Identifiler PCR Amplification Kit (Applied Biosystems; 
Norwalk, CT, USA), which simultaneously amplifies 15 STR 
loci and the gender-determination marker Amelogenin. The 
PCR products were analyzed using ABI 3100 Genetic 
Analyzer (Applied Biosystems). Fluorescence was quantified, 
and the precise size of the DNA fragments was calculated 
with the Genotyper software (Applied Biosystems). The per-Korean J Hematol 2011;46:18-23.
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Table 2. Chimerism analysis of relapsed time after transplantation.
Relapsed 
time (days)
after transplant
Recipient-
derived
NCs (%)
Recipient-
derived 
T cells (%)
Recipient-
derived 
NK cells (%)
UPN 3
UPN 7
UPN 10
553
29
64
64.8
100.0
15.4
0.0
100.0
NA
100.0
100.0
100.0
Abbreviations: NCs, nucleated cells; NK cells, natural killer cells;
UPN, unique patient number; NA, not applicable.
Table 3. Correlation between the lineage-specific mixed/100% 
recipient chimerism and clinical outcome.
NCs T cells NK cells
Number of relapses
P-value
Number of mortalities
P-value
Number of occurrences
  of acute GVHD
P-value
Number of occurrences
  of chronic GVHD
P-value
8/9
0.000
6/9 
0.007
4/9
NS
6/10
NS
3/6
NS
4/6
0.046
2/9
NS
3/10
NS
3/5
NS
4/5
0.013
2/9
NS
1/10
NS
The Pearson chi-square test was used to analyze the relationship
of donor-type chimerism with relapse and mortality after 
allogeneic stem cell transplantation.
Abbreviations: NCs, nucleated cells; NK cells, natural killer cells;
GVHD, graft-versus-host disease; NS, not significant.
centages of donor and recipient DNA were calculated from 
each pair of informative STR markers on the basis of in-
dividual proportions of donor (D) and recipient (R) peak 
areas in relation to the summation of all signals, for example, 
recipient’s DNA (%)=(R1+R2)/(D1+D2+R1+R2)×100.
3. Definition of MC
  CC was defined as the presence of ＞95% donor-type 
hematopoietic cells after allo-SCT. Patients with CC at a 
certain time point after transplantation can develop a state 
of MC. MC is defined as the presence of 5-95% donor-type 
hematopoietic cells. Split chimerism was defined as CC in 
one cell type and the presence of recipient-derived cells 
(totally or in-part) in others.
4. Statistical analysis
  All statistical analyses were conducted using the SPSS 
12.0 statistical package for Windows (SPSS; Chicago, IL, 
USA). A P-value of ＜0.05 was considered to be statically 
significant.
RESULTS
1. Clinical outcome of patients
  The characteristics and clinical data of 24 patients are 
presented in Table 1. Allo-SCT was performed with a median 
of 3.8×10
6 CD34
＋ cells/kg (range, [0.16-7.58]×10
6 CD34
＋ 
cells/kg). The median follow-up period after transplantation 
was 19 months (range, 1-59 months). The median periods 
required for recovering the absolute counts of neutrophils 
(＞500/μL) and platelets (＞20,000/μL) were 16 days (range, 
11-40 days) and 25 days (range, 17-60 days), respectively. 
The number of informative STR markers in donor-recipient 
pairs ranged from 4 to 15 (median, 9). The markers were 
from a set of 16 polymorphic loci, including D18S51, 
D8S1179, D16S539, D2S1338 and FGA, which were the most 
informative loci, and the loci were amplified in 16 or 17 
donor-recipient pairs.
2. Chimerism analysis of patients
  Among the 24 patients, 23 achieved engraftment and only 
1 patient (unique patient number [UPN] 7) did not. Twenty- 
two patients achieved CC in NCs after a median of 23 days 
(range, 12-39 days), and 1 patient (UPN 17) achieved CC 
after 103 days. One patient (UPN 2) underwent trans-
plantation before the assessment of chimerism by multiplex 
STR-PCR. NC chimerism was analyzed more than 4 times 
in all patients (except UPN 2), and the results in T cells 
and NK cells during the early engraftment period (≤30 
days after transplantation) could not be confirmed because 
of low cell numbers.
  1) Correlation between chimerism status and relapse
  Nine, 6, and 5 patients had 100% recipient-derived NCs, 
T cells, and NK cells or MC in these cells, respectively. 
Among these 9, 6, and 5 patients, relapse occurred in 8, 
3, and 3 patients, respectively. Further, 3 patients (UPNs 
3, 7, and 10) with relapse had 100% recipient-derived NK 
cells; NCs and T cells comprised various percentages of recipi-
ent-derived cells (Table 2). Patients with relapse had MC 
or 100% recipient-derived cells in a part cell type and/or 
all cell types. In two patients (UPNs 5 and 11), MC in NCs 
was detected after relapse was clinically diagnosed. MC in 
NCs (P=0.000), but not in T cells and NK cells (P＞0.05), 
was significantly correlated with disease relapse (Table 3).
  2) Correlation between chimerism status and mortality
  Among the 24 patients, 8 died between days 80 and 571 
(median, 307 days). Five patients died because of a relapse 
or progressive disease (AML, 2; CML, 1; ALL, 1; and myelo-
dysplastic syndrome [MDS], 1) and 3 patients died because 
of transplant-related complications such as pneumonia. 
These dead patients included 6 out of the 9 patients with 
MC in NCs or 100% recipient-derived NCs (P=0.007).
  Patients (4/6) with MC in T cells or 100% recipient-derived 
T cells (P=0.046) and 4/5 patients with MC in NK cells 
or 100% recipient-derived NK cells (P=0.013) died. The re-
sults of all lineage-specific chimerism analyses were sig-
nificantly correlated with mortality (Table 3). Of the 8 re-
lapsed patients who had MC in NCs or 100% recipi-
ent-derived NCs, 4 received donor lymphocyte infusion 
(DLI) at a median of 252 days (range, 104-457 days); among Korean J Hematol 2011;46:18-23.
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Table 4. Results of lineage-specific chimerism analysis of UPN 19.
Time (days)
after transplant
Recipient-
derived
NCs (%)
Recipient-
derived
T cells (%)
Recipient-
derived
NK cells (%)
14
32
93
105
119
162
274
0.0
7.2
0.0
0.0
0.0
0.0
0.0
NA
29.0
19.5
0.0
18.5
0.0
0.0
NA
0.0
0.0
0.0
0.0
0.0
0.0
Abbreviations: NCs, nucleated cells; NK cells, natural killer cells; 
NA, not applicable.
Fig. 1. Chimerism results of unique patient number (UPN) 5 and UPN 11 after donor lymphocyte infusion (DLI). Four patients who received DLI
(excluding UPN 11) showed mixed chimerism or relapse. UPN 11 maintained 100% donor chimerism during 867 days. UPN 5 had acute 
graft-versus-host disease after DLI. Abbreviations: DLI, donor lymphocyte infusion; GVHD, graft-versus-host disease; NCs, nucleated cells; NK,
natural killer.
these, 1 patient (UPN 11) maintained complete remission 
during 867 days and 3 patients (UPNs, 1, 5, and 7) died 
because of secondary relapse (Fig. 1).
  3) Correlation between chimerism status and acute/chronic 
GVHD
  Of the total of 24 patients, 9 (37.5%) developed acute 
GVHD, and 3 of them developed the condition after DLI. 
Of the 9 patients with acute GVHD, 4, 2, and 2 patients 
had 100% recipient-derived NCs, T cells, and NK cells or 
MC in these cells, respectively. MC in all cell types was 
not significantly correlated with the incidence of acute 
GVHD (P＞0.05). Of the 24 patients, 10 (41.6%) had ex-
tensive chronic GVHD. Among these patients, 6, 3, and 
1 patients had 100% recipient-derived NCs, T cells, and 
NK cells or MC in these cells, respectively. Six patients had 
MC in T cells, and 3 of them had chronic GVHD. In UPN 
19, T cells consisted of 29.0%, 19.5%, and 18.5% recipient 
cells on days 32, 93, and 119, respectively, and chronic GVHD 
was observed continuously from days 130 to 220 (Table 4). 
UPNs 3 and 6 had MC in T cells around the onset of chronic 
GVHD. Two patients (UPNs 7 and 10) with MC in T cells 
had acute GVHD. Another patient (UPN 24) did not have 
acute/chronic GVHD. Four of the 10 patients with chronic 
GVHD showed CC in all cell types. MC in all cell types 
was not correlated with the incidence of acute and chronic 
GVHD (P＞0.05;  Table 3). 
DISCUSSION
  Chimerism analyses are routinely performed to monitor 
engraftment [1-4]. The persistence or reappearance of autolo-
gous cells has often been observed after SCT. Several studies 
performed during the last 20 years have reported that MC 
is associated with graft rejection [11, 16-20]. Chimerism anal-
ysis is still controversial because some studies did not find a 
correlation between chimerism and disease relapse [21, 22]. 
  In this study, we analyzed the chimerism status of NCs, 
T cells, and NK cells from myeloablative allo-SCT patients 
by using multiplex STR-PCR and determined the correlation 
between these results and the clinical outcome. We found 
that among the patients observed, 9 had MC in NCs or 
100% recipient-derived NCs, and the disease relapsed in 
all the patients, except UPN 19. In 2 patients, MC in NCs 
was detected after the clinical diagnosis of relapse. This may 
be explained by the long intervals between chimerism analy-
sis and SCT, which increase the risk of overlooking a rapidly 
evolving MC before hematological relapse. MC in NCs was 
significantly correlated with disease relapse. Five patients 
had MC in NK cells or 100% recipient-derived NK cells, 
and 3 of these patients had 100% recipient-derived NK cells. 
NCs and T cells comprised recipient-derived cells in various 
proportions. NK cells were not significantly correlated with 
r e l a p s e  d e s p i t e  M C  i n  N K  c e l l s in patients with disease 
relapse. Baron et al. [17] found that in patients who had Korean J Hematol 2011;46:18-23.
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undergone non-myeloablative SCT, low donor T-cell and 
NK-cell chimerism levels on day 14 were associated with 
high probabilities of graft rejection and that an early estab-
lishment of donor NK-cell chimerism was associated with 
better progression-free survival. We found that the chimer-
ism status differed among different cell lineages in 6 patients 
with myeloid malignancies (UPNs 3, 6, 10, 15, 19, and 24). 
Four out of the 6 cases were published previously [23]. Zeiser 
et al. [18] reported that conventional chimerism analysis 
had lower sensitivity (＜3%) than lineage-specific chimerism 
analysis (0.1%). Patients with MC in NK cells or 100% recipi-
ent-derived NK cells were diagnosed with AML or MDS. 
One patient (UPN 15) with AML had 54.5% blasts in the 
B M  a n d  n o  b l a s t s  i n  t h e  P B .  F e w  s t u d i e s  h a v e  r e p o r t e d  
relapse in the BM without prior detection of recipient cells 
in the PB [24]. Myeloblasts were not CD56-positive at the 
time of diagnosis in any of the cases. However, we could 
not totally exclude the possibility that the blasts expressed 
low levels of CD56 from the onset or acquired the ectopic 
marker during treatment or relapse. The data supported the 
concept that persistence of MC in NK cells in patients with 
AML and MDS reduces the graft-versus-malignancy (GVM) 
effect and helps to promote relapse. Clausen et al. [25] found 
that a grafted NK cell dose was associated with a lower 
risk of relapse and improved survival.
  We confirmed that the presence of 100% recipient-derived 
NCs, T cells, and NK cells or MC in these cells was correlated 
with mortality. This observation indicated the importance 
of short interval chimerism analysis; immediate therapeutic 
intervention is needed if an increase in the level of MC 
is noted. The role of DLI in patients with relapse is unclear 
[18, 26]. In this study, 4 patients with MC and relapse received 
DLI, and all, except UPN 11, had secondary relapse. In the 
present study, patients who had developed increased MC 
and, therefore, received additional DLI did not have en-
hanced GVM effect, and autologous hematopoiesis could 
not be eliminated. McSweeney et al. [27] recommended con-
sider DLI for declining donor chimerism, but a higher than 
20% of donor T cells chimerism, stable MC of ＞2 weeks, 
or progressive disease. Further evidence of reduced allor-
eactivity in patients with MC is provided by a lower incidence 
of severe acute GVHD and a higher incidence of relapse 
in patients with MC after SCT than in patients with CC 
[28, 29]. Michallet et al. [28] showed a significant correlation 
between chimerism status and overall survival as well as 
between chimerism status and the incidences of acute and 
chronic GVHD. Mattsson et al. [29] reported that about 
82% of patients had MC for donor/host T cells at the onset 
o f  a c u t e  G V H D .  I n  t h i s  s t u d y ,  M C  i n  a l l  c e l l  t y p e s  w a s  
not correlated with the incidence of acute and chronic 
GVHD. However, 6 patients showed MC in T cells, and 
3 (UPNs 3, 6, 19) of these patients had chronic GVHD. 
UPNs 7 and 10 with MC in T cells had acute GVHD. Although 
no clear conclusion could be made because of the lack of 
statistically significant correlation, MC in T cells may influ-
ence GVHD.
  In the case of high-risk patients or when other suitable 
disease markers are not available, sequential chimerism anal-
ysis in leukocyte subsets permits early detection of relapse 
and facilitates the monitoring of therapeutic interventions. 
Furthermore, prospective clinical studies should include 
large numbers of patients with the same disease. Despite 
the above-mentioned drawbacks; we believe that these chi-
merism data could be used as the fundamental basis for 
monitoring the outcome of myeloablative SCT, which is 
commonly performed in Korea.
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